- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00002411
A Comparison of Two Triple-Drug Combinations in Patients Who Have Never Been Treated With Anti-HIV Drugs
A Randomized Study of the Long-Term Suppression of Plasma HIV RNA Levels by Triple Combination Regimens in Treatment Naive Subjects
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35203
- Sorra Research Ctr / Med Forum
-
-
Arizona
-
Phoenix, Arizona, Forenede Stater, 85016
- Body Positive
-
-
California
-
Fresno, California, Forenede Stater, 93710
- Hill Top Research Inc
-
Los Angeles, California, Forenede Stater, 900276069
- Aids Healthcare Foundation
-
Los Angeles, California, Forenede Stater, 90024
- UCLA Med Ctr / CARE BH-412 CHS
-
Los Angeles, California, Forenede Stater, 90073
- West Los Angeles VAMC
-
Sherman Oaks, California, Forenede Stater, 91403
- Sherman Oaks Hosp Research Institute
-
Torrance, California, Forenede Stater, 90502
- Harbor UCLA Med Ctr / Research and Educational Institute
-
-
Connecticut
-
New Haven, Connecticut, Forenede Stater, 06504
- Yale New Haven Hosp / Nathan Smith Clinic
-
-
District of Columbia
-
Washington, District of Columbia, Forenede Stater, 20037
- GW Med Ctr / Clinical Trials Unit
-
-
Florida
-
Fort Lauderdale, Florida, Forenede Stater, 33308
- Med Alternatives
-
Fort Lauderdale, Florida, Forenede Stater, 33316
- Urgent Care Ctr
-
Miami, Florida, Forenede Stater, 33142
- Specialty Med Care Ctrs of South Florida Inc
-
Tampa, Florida, Forenede Stater, 33602
- Hillsborough County Health Dept
-
Tampa, Florida, Forenede Stater, 33602
- Saint Josephs Hosp
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60611
- Northwestern Univ / Div of Infect Diseases
-
Chicago, Illinois, Forenede Stater, 60612
- Rush Presbyterian / ST Lukes Med Ctr
-
-
Kansas
-
Wichita, Kansas, Forenede Stater, 67214
- Univ of Kansas School of Medicine / Office of Rsch
-
-
Kentucky
-
Lexington, Kentucky, Forenede Stater, 405360226
- Ky Clinic Annex #4 / Room 205E / Speed Sort #0284
-
-
New Hampshire
-
Lebanon, New Hampshire, Forenede Stater, 03756
- Dartmouth-Hitchcock Med Ctr
-
-
New Jersey
-
Newark, New Jersey, Forenede Stater, 07103
- NJCRI
-
Somerville, New Jersey, Forenede Stater, 08876
- Infectious Disease Assoc of Central Jersey
-
-
New York
-
Farmingdale, New York, Forenede Stater, 11735
- UCT International
-
New York, New York, Forenede Stater, 10011
- St Luke Roosevelt Hosp
-
Rochester, New York, Forenede Stater, 14642
- St Mary's Hosp (Univ of Rochester/Infectious Diseases)
-
Stony Brook, New York, Forenede Stater, 117948153
- SUNY at Stony Brook / Div of Infectious Disease
-
-
North Carolina
-
Charlotte, North Carolina, Forenede Stater, 28207
- Nalle Clinic / Clinical Research Dept
-
-
Oklahoma
-
Tulsa, Oklahoma, Forenede Stater, 74114
- Associates in Med and Mental Health
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19107
- Stephen P Hauptman
-
-
South Carolina
-
Charleston, South Carolina, Forenede Stater, 29425
- Med Univ of South Carolina / Div of Infect Disease
-
-
Texas
-
Galveston, Texas, Forenede Stater, 775550835
- Univ of Texas / Med Branch at Galveston
-
Houston, Texas, Forenede Stater, 77004
- Joseph C Gathe
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria
Patients must have:
Within 15 business days prior to randomization:
- CD4 cell count greater than or equal to 100 cells/mm3.
- HIV RNA greater than or equal to 2,000 copies/ml by Roche Amplicor Assay.
Exclusion Criteria
Co-existing Condition:
Patients with any of the following symptoms or conditions are excluded:
- Bilateral peripheral neuropathy.
- Intractable diarrhea.
- Proven or suspected acute hepatitis within 30 days prior to study entry.
Concurrent Medication:
Excluded:
- Therapy for any co-existing disease that may interfere with patient ability to participate in this study.
Concurrent Treatment:
Excluded:
Therapy for any co-existing disease that may interfere with patient ability to participate in this study.
Patients with the following prior conditions are excluded:
History of acute or chronic pancreatitis.
Prior Medication:
Excluded:
- Therapy for any previous disease that may interfere with patient ability to participate in this study.
- Excluded within 14 days prior to randomization:
Greater than 4 weeks of nucleoside therapy or greater than 1 week of protease inhibitor therapy.
- Excluded within 3 months of the start of this study or expected need at time of enrollment:
- Agents with significant systemic myelosuppressive, neurotoxic, pancreatoxic, hepatotoxic, or cytotoxic potential.
- Inability to tolerate oral medication.
Prior Treatment:
Excluded:
Therapy for any previous disease that may interfere with patient ability to participate in this study.
Risk Behavior:
Excluded:
Active alcohol or substance abuse that, in the opinion of the investigator, is sufficient to prevent adequate compliance with study therapy or to increase the risk of developing pancreatitis.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- RNA-virusinfektioner
- Virussygdomme
- Infektioner
- Blodbårne infektioner
- Overførbare sygdomme
- Seksuelt overførte sygdomme, virale
- Seksuelt overførte sygdomme
- Lentivirus infektioner
- Retroviridae infektioner
- Immunologiske mangelsyndromer
- Sygdomme i immunsystemet
- HIV-infektioner
- Molekylære mekanismer for farmakologisk virkning
- Anti-infektionsmidler
- Antivirale midler
- Reverse transkriptasehæmmere
- Nukleinsyresyntesehæmmere
- Enzymhæmmere
- Anti-HIV-midler
- Anti-retrovirale midler
- Antimetabolitter
- Proteasehæmmere
- HIV-proteasehæmmere
- Virale proteasehæmmere
- Lamivudin
- Zidovudin
- Stavudine
- Didanosin
- Nelfinavir
Andre undersøgelses-id-numre
- 039E
- AI454-148
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .